United States Lymphoma Drugs Market Report 2018

February 2018 | 114 pages | ID: U2EE49CC2C9EN
QYResearch

Abstracts

In this report, the United States Lymphoma Drugs market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Lymphoma Drugs in these regions, from 2013 to 2025 (forecast).

United States Lymphoma Drugs market competition by top manufacturers/players, with Lymphoma Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Celgene
• Roche
• Johnson & Johnson
• Seattle Genetics
• Amgen
• Bristol-Myers Squibb
• Gilead Sciences
• GlaxoSmithKline
• Novartis
• Pfizer
• Takeda
• Teva

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Hodgkin Lymphoma (HL) Drugs
• Non-hodgkin Lymphoma (NHL) Drugs

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospitals
• Clinics
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Lymphoma Drugs Market Report 2018

1 LYMPHOMA DRUGS OVERVIEW

1.1 Product Overview and Scope of Lymphoma Drugs
1.2 Classification of Lymphoma Drugs by Product Category
  1.2.1 United States Lymphoma Drugs Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Lymphoma Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 Hodgkin Lymphoma (HL) Drugs
  1.2.4 Non-hodgkin Lymphoma (NHL) Drugs
1.3 United States Lymphoma Drugs Market by Application/End Users
  1.3.1 United States Lymphoma Drugs Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Hospitals
  1.3.3 Clinics
  1.3.4 Others
1.4 United States Lymphoma Drugs Market by Region
  1.4.1 United States Lymphoma Drugs Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Lymphoma Drugs Status and Prospect (2013-2025)
  1.4.3 Southwest Lymphoma Drugs Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Lymphoma Drugs Status and Prospect (2013-2025)
  1.4.5 New England Lymphoma Drugs Status and Prospect (2013-2025)
  1.4.6 The South Lymphoma Drugs Status and Prospect (2013-2025)
  1.4.7 The Midwest Lymphoma Drugs Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Lymphoma Drugs (2013-2025)
  1.5.1 United States Lymphoma Drugs Sales and Growth Rate (2013-2025)
  1.5.2 United States Lymphoma Drugs Revenue and Growth Rate (2013-2025)

2 UNITED STATES LYMPHOMA DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Lymphoma Drugs Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Lymphoma Drugs Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Lymphoma Drugs Average Price by Players/Suppliers (2013-2018)
2.4 United States Lymphoma Drugs Market Competitive Situation and Trends
  2.4.1 United States Lymphoma Drugs Market Concentration Rate
  2.4.2 United States Lymphoma Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Lymphoma Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES LYMPHOMA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Lymphoma Drugs Sales and Market Share by Region (2013-2018)
3.2 United States Lymphoma Drugs Revenue and Market Share by Region (2013-2018)
3.3 United States Lymphoma Drugs Price by Region (2013-2018)

4 UNITED STATES LYMPHOMA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Lymphoma Drugs Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Lymphoma Drugs Revenue and Market Share by Type (2013-2018)
4.3 United States Lymphoma Drugs Price by Type (2013-2018)
4.4 United States Lymphoma Drugs Sales Growth Rate by Type (2013-2018)

5 UNITED STATES LYMPHOMA DRUGS SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Lymphoma Drugs Sales and Market Share by Application (2013-2018)
5.2 United States Lymphoma Drugs Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES LYMPHOMA DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Celgene
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Lymphoma Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Celgene Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 Roche
  6.2.2 Lymphoma Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Roche Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Johnson & Johnson
  6.3.2 Lymphoma Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Johnson & Johnson Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Seattle Genetics
  6.4.2 Lymphoma Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Seattle Genetics Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Amgen
  6.5.2 Lymphoma Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Amgen Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Bristol-Myers Squibb
  6.6.2 Lymphoma Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Bristol-Myers Squibb Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Gilead Sciences
  6.7.2 Lymphoma Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Gilead Sciences Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 GlaxoSmithKline
  6.8.2 Lymphoma Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 GlaxoSmithKline Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Novartis
  6.9.2 Lymphoma Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Novartis Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 Pfizer
  6.10.2 Lymphoma Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Pfizer Lymphoma Drugs Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview
6.11 Takeda
6.12 Teva

7 LYMPHOMA DRUGS MANUFACTURING COST ANALYSIS

7.1 Lymphoma Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Lymphoma Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Lymphoma Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Lymphoma Drugs Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES LYMPHOMA DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Lymphoma Drugs Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Lymphoma Drugs Sales Volume Forecast by Type (2018-2025)
11.3 United States Lymphoma Drugs Sales Volume Forecast by Application (2018-2025)
11.4 United States Lymphoma Drugs Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Lymphoma Drugs
Figure United States Lymphoma Drugs Market Size (K Units) by Type (2013-2025)
Figure United States Lymphoma Drugs Sales Volume Market Share by Type (Product Category) in 2017
Figure Hodgkin Lymphoma (HL) Drugs Product Picture
Figure Non-hodgkin Lymphoma (NHL) Drugs Product Picture
Figure United States Lymphoma Drugs Market Size (K Units) by Application (2013-2025)
Figure United States Sales Market Share of Lymphoma Drugs by Application in 2017
Figure Hospitals Examples
Table Key Downstream Customer in Hospitals
Figure Clinics Examples
Table Key Downstream Customer in Clinics
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Lymphoma Drugs Market Size (Million USD) by Region (2013-2025)
Figure The West Lymphoma Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Lymphoma Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Lymphoma Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Lymphoma Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Lymphoma Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Lymphoma Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Lymphoma Drugs Sales (K Units) and Growth Rate (2013-2025)
Figure United States Lymphoma Drugs Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Lymphoma Drugs Market Major Players Product Sales Volume (K Units) (2013-2018)
Table United States Lymphoma Drugs Sales (K Units) of Key Players/Suppliers (2013-2018)
Table United States Lymphoma Drugs Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Lymphoma Drugs Sales Share by Players/Suppliers
Figure 2017 United States Lymphoma Drugs Sales Share by Players/Suppliers
Figure United States Lymphoma Drugs Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Lymphoma Drugs Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Lymphoma Drugs Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Lymphoma Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Lymphoma Drugs Revenue Share by Players/Suppliers
Table United States Market Lymphoma Drugs Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)
Figure United States Market Lymphoma Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2017
Figure United States Lymphoma Drugs Market Share of Top 3 Players/Suppliers
Figure United States Lymphoma Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Lymphoma Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Lymphoma Drugs Product Category
Table United States Lymphoma Drugs Sales (K Units) by Region (2013-2018)
Table United States Lymphoma Drugs Sales Share by Region (2013-2018)
Figure United States Lymphoma Drugs Sales Share by Region (2013-2018)
Figure United States Lymphoma Drugs Sales Market Share by Region in 2017
Table United States Lymphoma Drugs Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Lymphoma Drugs Revenue Share by Region (2013-2018)
Figure United States Lymphoma Drugs Revenue Market Share by Region (2013-2018)
Figure United States Lymphoma Drugs Revenue Market Share by Region in 2017
Table United States Lymphoma Drugs Price (USD/Unit) by Region (2013-2018)
Table United States Lymphoma Drugs Sales (K Units) by Type (2013-2018)
Table United States Lymphoma Drugs Sales Share by Type (2013-2018)
Figure United States Lymphoma Drugs Sales Share by Type (2013-2018)
Figure United States Lymphoma Drugs Sales Market Share by Type in 2017
Table United States Lymphoma Drugs Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Lymphoma Drugs Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Lymphoma Drugs by Type (2013-2018)
Figure Revenue Market Share of Lymphoma Drugs by Type in 2017
Table United States Lymphoma Drugs Price (USD/Unit) by Types (2013-2018)
Figure United States Lymphoma Drugs Sales Growth Rate by Type (2013-2018)
Table United States Lymphoma Drugs Sales (K Units) by Application (2013-2018)
Table United States Lymphoma Drugs Sales Market Share by Application (2013-2018)
Figure United States Lymphoma Drugs Sales Market Share by Application (2013-2018)
Figure United States Lymphoma Drugs Sales Market Share by Application in 2017
Table United States Lymphoma Drugs Sales Growth Rate by Application (2013-2018)
Figure United States Lymphoma Drugs Sales Growth Rate by Application (2013-2018)
Table Celgene Basic Information List
Table Celgene Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Celgene Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Celgene Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Celgene Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Roche Basic Information List
Table Roche Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Roche Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Roche Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Roche Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Johnson & Johnson Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Johnson & Johnson Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Johnson & Johnson Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Seattle Genetics Basic Information List
Table Seattle Genetics Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Seattle Genetics Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Seattle Genetics Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Seattle Genetics Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Amgen Basic Information List
Table Amgen Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Amgen Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Amgen Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Amgen Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Bristol-Myers Squibb Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Bristol-Myers Squibb Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Bristol-Myers Squibb Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Gilead Sciences Basic Information List
Table Gilead Sciences Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Gilead Sciences Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Gilead Sciences Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Gilead Sciences Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure GlaxoSmithKline Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure GlaxoSmithKline Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure GlaxoSmithKline Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Novartis Basic Information List
Table Novartis Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Novartis Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Novartis Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Novartis Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Pfizer Basic Information List
Table Pfizer Lymphoma Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)
Figure Pfizer Lymphoma Drugs Sales Growth Rate (2013-2018)
Figure Pfizer Lymphoma Drugs Sales Market Share in United States (2013-2018)
Figure Pfizer Lymphoma Drugs Revenue Market Share in United States (2013-2018)
Table Takeda Basic Information List
Table Teva Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Lymphoma Drugs
Figure Manufacturing Process Analysis of Lymphoma Drugs
Figure Lymphoma Drugs Industrial Chain Analysis
Table Raw Materials Sources of Lymphoma Drugs Major Players/Suppliers in 2017
Table Major Buyers of Lymphoma Drugs
Table Distributors/Traders List
Figure United States Lymphoma Drugs Sales Volume (K Units) and Growth Rate Forecast (2018-2025)
Figure United States Lymphoma Drugs Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Lymphoma Drugs Price (USD/Unit) Trend Forecast (2018-2025)
Table United States Lymphoma Drugs Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Lymphoma Drugs Sales Volume (K Units) Forecast by Type (2018-2025)
Figure United States Lymphoma Drugs Sales Volume (K Units) Forecast by Type in 2025
Table United States Lymphoma Drugs Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Lymphoma Drugs Sales Volume (K Units) Forecast by Application (2018-2025)
Figure United States Lymphoma Drugs Sales Volume (K Units) Forecast by Application in 2025
Table United States Lymphoma Drugs Sales Volume (K Units) Forecast by Region (2018-2025)
Table United States Lymphoma Drugs Sales Volume Share Forecast by Region (2018-2025)
Figure United States Lymphoma Drugs Sales Volume Share Forecast by Region (2018-2025)
Figure United States Lymphoma Drugs Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources